关键词：乳腺肿瘤；免疫组织化学；人表皮生长因子受体2；表皮生长因子受体；雌激素调节蛋白；雌激素受体

    摘要：目的 探讨人表皮生长因子受体2(Her-2)、表皮生长因子受体(EGFR)、雌激素调节蛋白(PS-2)、雌激素受体(ER)在乳腺癌中的表达及其临床意义。方法 用免疫组织化学方法检测108例乳腺癌患者Her-2、EGFR、PS-2、ER的表达情况，并进行比较。 结果 Her-2、EGFR、PS-2、ER表达阳性者分别为40例 (37.0%)、44例 (40.7%)、62例 (57.4%)和58例 (53.7%)。Her-2的表达与EGFR无相关性(P>0.05 )，与PS-2呈负相关(P<0.05)，与ER呈负相关(P<0.05)。Her-2、EGFR、PS-2、ER表达与乳腺癌的组织学分级相关(P<0.05)。Her-2、EGFR、ER表达与淋巴结转移相关(P<0.05)，Her-2、EGFR、PS-2、ER与乳腺癌的病理学类型、患者年龄及肿瘤大小无关 (P>0 .05 )。结论 乳腺癌中Her-2、EGFR表达提示患者预后不良；PS-2、ER表达提示患者预后良好；Her-2、EGFR、PS-2、ER是判断乳腺癌预后的有效指标。

    Expressions of Her-2, EGFR, PS-2 and ER in breast cancer and their clinical implications

    XU Lei¹, BAI Zhong-hong¹, XU Ruan-cheng¹, YAN Hui¹, WANG Fang-ju¹, LUO Rong-cheng<sup>2

    1</sup>Department of Oncology, 91 Hospital of PLA, Jiaozuo 454003, China; ²Oncology Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

    Abstract: Objective To detect the expressions of human epidermal growth factor receptor 2 (Her-2), epidermal growth factor receptor (EGFR), presenilin 2 (PS-2) and estrogen receptor (ER) in breast cancer and discuss their clinical implications. Methods The expressions of Her-2, EGFR, PS-2 and ER were measured immunohistochemically in 108 patients with breast cancer. Results The positive expression rates of Her-2, EGFR, PS-2 and ER were 37.0%, 40.7%, 57.4% and 53.7% respectively in the breast cancer patients. The expression of Her-2 was not correlated with EGFR, but inversely correlated with PS-2 and ER. The expressions of Her-2 and EGFR, PS-2, ER were correlated with the histological grades (P<0.05), and Her-2, EGFR and ER expressions with lymph node metastasis (P<0.05). The expressions of Her-2, EGFR, PS-2 and ER did not correlate to the pathological types, patient’s age and tumor size (P>0.05). Conclusion Expressions of Her-2 and EGFR often suggests an unfavorable prognosis while expression of PS-2 and ER suggests a more favorable one. Expressions of Her-2, EGFR, PS-2 and ER are useful prognostic factors in breast cancer patients. ......